NGM Biopharmaceuticals (NYSE:NGM) Director Peter Svennilson purchased 28,056 shares of the firm’s stock in a transaction on Tuesday, July 30th. The stock was bought at an average cost of $13.68 per share, with a total value of $383,806.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Peter Svennilson also recently made the following trade(s):
- On Friday, June 14th, Peter Svennilson purchased 29,760 shares of NGM Biopharmaceuticals stock. The stock was bought at an average cost of $14.05 per share, with a total value of $418,128.00.
- On Tuesday, May 7th, Peter Svennilson purchased 57,000 shares of NGM Biopharmaceuticals stock. The stock was bought at an average cost of $14.10 per share, with a total value of $803,700.00.
Shares of NYSE:NGM opened at $14.21 on Friday. NGM Biopharmaceuticals has a 12-month low of $12.00 and a 12-month high of $18.75. The firm has a 50 day moving average of $13.93.
NGM has been the subject of a number of analyst reports. Goldman Sachs Group initiated coverage on NGM Biopharmaceuticals in a report on Monday, April 29th. They issued a “buy” rating and a $22.00 price target for the company. Cowen reissued a “buy” rating and issued a $25.00 price target on shares of NGM Biopharmaceuticals in a report on Monday, May 20th. Stifel Nicolaus initiated coverage on NGM Biopharmaceuticals in a report on Monday, June 24th. They issued a “buy” rating and a $26.00 price target for the company. Finally, Citigroup initiated coverage on NGM Biopharmaceuticals in a report on Monday, April 29th. They issued a “buy” rating and a $29.00 price target for the company.
An institutional investor recently bought a new position in NGM Biopharmaceuticals stock. Candriam Luxembourg S.C.A. bought a new position in shares of NGM Biopharmaceuticals (NYSE:NGM) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 135,000 shares of the company’s stock, valued at approximately $1,968,000. Candriam Luxembourg S.C.A. owned about 0.20% of NGM Biopharmaceuticals at the end of the most recent quarter.
NGM Biopharmaceuticals Company Profile
NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.
Featured Story: What are different types of coverage ratios?
Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.